Phospho-NTRK1 (Tyr680/681) Antibody

What is NTRK1 and what specific role does phosphorylation at Tyr680/681 play in its function?

NTRK1 (Neurotrophic Tyrosine Kinase Receptor Type 1), also known as TrkA, is a receptor tyrosine kinase essential for the development and survival of neurons, particularly sensory neurons involved in pain, temperature, and touch perception. NTRK1 functions as a high-affinity receptor for nerve growth factor (NGF) .

Phosphorylation at Tyr680/681 occurs within the activation loop of the NTRK1 kinase domain and is crucial for receptor activation. When NGF binds to NTRK1, the receptor undergoes homodimerization followed by autophosphorylation at multiple tyrosine residues, including Tyr680/681 . This phosphorylation event is required for full kinase activation and downstream signaling through several pathways:

• PI3K/AKT pathway (survival signaling)

• Ras/MAPK pathway (differentiation and growth)

• PLCγ pathway (calcium signaling)

These pathways collectively regulate neuronal growth, differentiation, and survival . Mutations or dysfunction affecting the phosphorylation at these sites can lead to neurological disorders or contribute to oncogenic signaling when aberrantly activated.

What applications are commercially available Phospho-NTRK1 (Tyr680/681) antibodies validated for?

Phospho-NTRK1 (Tyr680/681) antibodies have been validated for multiple experimental applications:

Most phospho-specific antibodies detect endogenous levels of NTRK1 only when phosphorylated at the specified tyrosine residues (Tyr680+Tyr681), making them valuable tools for studying the activation state of the receptor .

It's important to note that antibody validation should be performed in your specific experimental system. Recent research has shown that of seven commercially available NTRK1 antibodies tested in knockout mouse models, only one demonstrated true specificity in western blotting applications .

How should researchers validate Phospho-NTRK1 (Tyr680/681) antibodies before experimental use?

Validation of phospho-specific antibodies is crucial for reliable research outcomes. A comprehensive validation approach should include:

• Genetic controls: Use of NTRK1 knockout tissues/cells as negative controls

  • Recent research demonstrated that many commercial NTRK1 antibodies failed specificity tests when validated against knockout samples

• Phosphatase treatment controls:

  • Split your sample and treat half with lambda phosphatase to remove phosphorylation

  • The phospho-specific antibody should only detect a signal in the untreated sample

• Stimulation experiments:

  • Treat cells with NGF (100 ng/ml for 5-15 minutes) to induce phosphorylation

  • Compare stimulated vs. unstimulated samples

• Peptide competition assays:

  • Pre-incubate antibody with phosphorylated and non-phosphorylated peptides

  • Signal should be blocked only by the phospho-peptide

• Cross-reactivity assessment:

  • Test for cross-reactivity with other phosphorylated TRK family members (TRKB, TRKC)

  • Verify specificity against other similar phosphorylation sites (e.g., Tyr674/675, Tyr701)

As demonstrated in recent literature, "Quality differences between various antibodies can affect their specificity, especially in the case of polyclonal antibodies... Thus, the results obtained here may not apply to antibodies from other lots or suppliers, even though product names and catalog numbers are identical."

Intermediate Research Questions

Optimized Western Blot Protocol for Phospho-NTRK1 (Tyr680/681):

Sample Preparation:

• Harvest cells rapidly to preserve phosphorylation status

• Lyse cells in buffer containing phosphatase inhibitors:

  • 25 mM Tris-HCl (pH 7.4)

  • 150 mM NaCl

  • 1% NP-40

  • 1% sodium deoxycholate

  • 0.1% sodium dodecyl sulfate

  • Protease/phosphatase inhibitor cocktail

• Homogenize and incubate on ice for 30 minutes

• Centrifuge at 15,000 rpm at 4°C for 15 minutes

• Recover supernatant and quantify protein using bicinchoninic acid (BCA) assay

SDS-PAGE and Transfer:

• Use fresh polyacrylamide gels (8-10%)

• Load 20-40 μg protein per lane

• Run at 100V through stacking gel, then 150V through resolving gel

• Transfer to PVDF membrane at 100V for 1 hour or 30V overnight at 4°C

Immunoblotting:

• Block in 2% skim milk in TBST for 1 hour at room temperature

• Incubate with Phospho-NTRK1 (Tyr680/681) antibody at 1:500-1:1000 dilution overnight at 4°C

• Wash 3 × 10 minutes with TBST

• Incubate with HRP-conjugated secondary antibody for 1 hour at room temperature

• Wash 3 × 10 minutes with TBST

• Develop using enhanced chemiluminescence (ECL)

Critical Considerations:

• Expected molecular weight: 140 kDa (fully glycosylated mature form)

• Additional bands may appear at 110 kDa (partially glycosylated) and 80 kDa (non-glycosylated)

• Include positive controls (NGF-stimulated cells) and negative controls (phosphatase-treated lysates)

• For validation using knockout models, prepare embryonic brain tissues from NTRK1 knockout mice

Research has demonstrated that the fully glycosylated, mature 140 kDa species of phospho-TrkA indicates active signaling in PD-1 treatment-resistant cancer cells .

What factors influence the specificity and cross-reactivity of Phospho-NTRK1 (Tyr680/681) antibodies?

Several factors can affect the specificity and potential cross-reactivity of phospho-specific NTRK1 antibodies:

• Antibody Production Method:

  • Polyclonal antibodies: Variable specificity between lots and suppliers

  • Monoclonal antibodies: Generally more consistent but may have more limited epitope recognition

• Epitope Conservation Across TRK Family:

  • High sequence similarity between activation loops of TRKA, TRKB, and TRKC can lead to cross-reactivity

  • The region surrounding Tyr680/681 in NTRK1 shares homology with corresponding regions in NTRK2 and NTRK3

• Antibody Production Process:

  • Higher specificity is achieved through sequential chromatography on phospho- and non-phospho-peptide affinity columns

  • Quality control during production significantly affects performance

• Experimental Conditions:

  • Buffer composition and pH can alter antibody binding characteristics

  • Fixation methods for IHC/IF can modify epitope accessibility

  • Denaturing conditions in Western blot versus native conditions in IF/IHC

• Cross-Reactivity with Other Phosphorylation Sites:

  • Proximity of Tyr680 and Tyr681 to other phosphorylation sites (e.g., Tyr674/675) may result in detection of multiple phosphorylated forms

  • Some antibodies may detect single-site phosphorylation (either Tyr680 or Tyr681) while others require both sites to be phosphorylated

Recent validation studies highlight the importance of testing specificity: "Of the seven antibodies tested, one showed specificity for NTRK1. Quality differences between various antibodies can affect their specificity, especially in the case of polyclonal antibodies."

How can Phospho-NTRK1 (Tyr680/681) antibodies be utilized to study NTRK fusion proteins in cancer research?

NTRK fusion proteins present unique challenges and opportunities for phospho-specific antibody applications in cancer research:

Methodological Approach for Studying NTRK1 Fusions:

• Detection Strategy for Fusion Proteins:

  • NTRK fusions typically retain the kinase domain containing Tyr680/681 while the N-terminal portion is replaced by the fusion partner

  • Phospho-NTRK1 (Tyr680/681) antibodies can detect activation of fusion proteins regardless of the 5' fusion partner

• Experimental Design for Fusion Protein Studies:

  • Cell line models: Transfect cells with cDNA constructs of NTRK1 fusions (e.g., TPM3-NTRK1, CD74-NTRK1, MPRIP-NTRK1)

  • Patient-derived xenografts: Establish from NTRK fusion-positive tumors

  • Protocol modifications: Use higher antibody concentrations (1:200-1:300) when detecting fusion proteins

• Multi-level Validation Approach:

  • Confirm NTRK fusion expression at mRNA level (RT-PCR)

  • Verify protein expression using pan-NTRK1 antibodies

  • Assess activation state using phospho-specific antibodies

  • "IHC should be used to confirm protein expression of NTRK fusions detected by nucleic acid-based testing since not all NTRK fusion genes are expressed and the protein kinase is the pharmacological target"

• Applications in Cancer Research:

  • Therapeutic response monitoring: Measure inhibition of Tyr680/681 phosphorylation following TRK inhibitor treatment

  • Resistance mechanisms: Identify persistent phosphorylation despite inhibitor treatment

  • Patient stratification: Correlate phosphorylation levels with clinical outcomes

• Case Study: PD-1 Resistance:
  Research has demonstrated that "three of four independent 344SQ PD-1 resistant cell lines showed upregulation of NTRK1 transcript levels, as well as increased phosphorylation of TrkA protein... the fully glycosylated, mature 140 kDa species of phospho-TrkA, suggesting that downstream signaling of TrkA is more active in these cells."

This approach can identify NTRK1 as a potential therapeutic target in cancers showing resistance to immunotherapy.

What methodological approaches can resolve contradictory findings when using different Phospho-NTRK1 antibodies?

When facing contradictory results between different phospho-NTRK1 antibodies, a systematic troubleshooting approach is necessary:

Hierarchical Validation Strategy:

• Comprehensive Antibody Validation Panel:

  • Test multiple antibodies against the same samples

  • Document lot numbers, production methods, and immunogen sequences

  • Create a comparison table documenting experimental conditions and results

  Antibody	Catalog #	Immunogen	Dilution	Controls	Result
  Example 1	AB-N03	Synthetic peptide (aa 680-690)	1:500	KO tissue	Nonspecific
  Example 2	#06-754	Recombinant protein	1:500	KO tissue	Specific

• Orthogonal Technique Validation:

  • Complement antibody-based methods with:

    • Mass spectrometry to directly identify phosphorylation sites

    • CRISPR/Cas9 engineering to create site-specific phosphorylation mutants (Y680F/Y681F)

    • In vitro kinase assays with purified proteins

• Genetic Model Systems:

  • Use NTRK1 knockout tissues/cells as definitive negative controls

  • "We evaluated the utility of commercial antibodies for NTRK1 using western blotting in brain lysates from NTRK1 knockout mice... We confirmed specificity for one of the seven commercial antibodies in western blots, in which the specific bands were absent in the knockout samples."

• Binding Site Analysis:

  • Conduct epitope mapping to identify precise binding regions

  • Distinguish between antibodies that recognize:

    • Single phosphorylation sites (either Tyr680 or Tyr681)

    • Dual phosphorylation (both Tyr680 and Tyr681)

    • Conformational epitopes dependent on phosphorylation

• Standardized Reporting Framework:

  • Document complete methods including:

    • Antibody source, catalog number, and lot number

    • Dilution and incubation conditions

    • Sample preparation methods

    • All controls used (positive, negative, and technical)

This systematic approach allows researchers to identify the most reliable antibody for their specific application and resolve contradictory findings between different antibodies.

How can phospho-specific antibodies be used to investigate the dynamics of NTRK1 signaling in neurological disorders?

Phospho-NTRK1 (Tyr680/681) antibodies provide powerful tools for investigating NTRK1 signaling dynamics in neurological contexts:

Advanced Experimental Approaches:

• Time-Course Analysis of Neuronal Activation:

  • Monitor phosphorylation kinetics following NGF stimulation (5, 15, 30, 60, 120 min)

  • Correlate with downstream signaling events (ERK, AKT, PLCγ activation)

  • Use phospho-specific antibodies for multiple NTRK1 sites to map signaling progression

• Spatial Mapping of NTRK1 Activation in Neural Tissues:

  • Utilize immunohistochemistry with phospho-NTRK1 antibodies to identify activation patterns

  • "Distinct signals were observed in regions with known NTRK1 expression, such as the striatum and basal forebrain. The characteristic expression pattern of NTRK1 in the paraventricular thalamic nucleus (PVT) was verified at the protein level, with high and low expression levels in the anterior and posterior PVT, respectively."

• Investigation of CIPA-Associated NTRK1 Mutations:

  • Models of congenital insensitivity to pain with anhidrosis (CIPA)

  • "NTRK1 gene mutations lead to the deletion of the tyrosine kinase domain... Many of the NTRK1 gene mutations lead to a protein that cannot be activated by phosphorylation, which means the mutated NTRK1 protein cannot transmit cell growth and survival signals to neurons."

  • Experimental design example:

    • Generate cell models expressing CIPA-associated NTRK1 mutations

    • Assess phosphorylation status at Tyr680/681 after NGF stimulation

    • Correlate phosphorylation defects with downstream signaling impairment

• Analysis of Splice Variants and Their Signaling Properties:

  • "The c.850 + 5G>A variant in NTRK1 resulted in two forms of aberrant mRNA splicing: 13bp deletion (c.838_850del13, p. Val280Ser fs180) and 25bp deletion (826_850del25, p. Val276Ser fs180) in exon 7, both leading to a translational termination at a premature stop codon and forming a C-terminal truncated protein."

  • Compare phosphorylation profiles between normal and aberrant splice variants

  • Identify differential signaling pathways activated by each variant

• Multi-Method Activation Assessment:

  • Combine phospho-antibody detection with functional readouts

  • Correlate phosphorylation status with:

    • Neurite outgrowth assays

    • Neuronal survival assays

    • Electrophysiological measurements

    • Calcium imaging

These advanced approaches enable researchers to dissect the complex relationship between NTRK1 phosphorylation status and neurological function or dysfunction in various disorders.

What are the most effective methods for quantifying changes in NTRK1 phosphorylation in response to therapeutic interventions?

For precise quantification of NTRK1 phosphorylation changes during therapeutic interventions, multiple complementary approaches should be employed:

Quantitative Phosphorylation Analysis Framework:

• Multiplexed Western Blot Analysis:

  • Simultaneously detect total and phospho-NTRK1 (Tyr680/681)

  • Calculate phosphorylation ratio (phospho/total) to normalize for expression differences

  • Use IRDye-conjugated secondary antibodies for two-color detection and precise quantification

  • Data analysis: Apply rolling ball background subtraction and normalization to housekeeping proteins

• ELISA-Based Quantification Systems:

  • Sandwich ELISA with capture antibody against total NTRK1 and detection antibody against phospho-NTRK1

  • Standard curve generation using recombinant phosphorylated NTRK1 protein

  • Dynamic range: Typically 0.1-10 ng/ml of phosphorylated NTRK1

  • Example protocol: Use antibody dilution of 1:5000 for highest sensitivity

• High-Content Imaging Analysis:

  • Immunofluorescence staining with phospho-NTRK1 (Tyr680/681) antibodies

  • Automated image acquisition and analysis of subcellular phospho-NTRK1 distribution

  • Quantification metrics:

    • Mean fluorescence intensity

    • Phospho-NTRK1 granule count and size

    • Membrane/cytoplasmic ratio of phospho-NTRK1

• Phospho-Flow Cytometry:

  • Single-cell quantification of NTRK1 phosphorylation

  • Protocol adaptations:

    • Permeabilization with methanol (-20°C) for 15 minutes

    • Primary antibody incubation: 1:100 dilution, 1 hour at room temperature

    • Secondary antibody: AF488 or PE-conjugated, 1:200 dilution

• Treatment Response Monitoring:

  • Baseline measurement: Pre-treatment phosphorylation assessment

  • Early response: 1-6 hour timepoints to catch rapid signaling changes

  • Sustained response: 24-72 hour timepoints to assess long-term adaptation

  • Drug removal: Phosphorylation rebound after treatment cessation

• Case Study Application - NTRK Inhibitor Therapy:

  • "We demonstrate that AZD4547, a highly potent and selective inhibitor of fibroblast growth factor receptor (FGFR), displays anti-tumor activity against KM12(Luc) cells harboring TPM3-NTRK1 fusion"

  • In such studies, phospho-NTRK1 antibodies enable direct quantification of target engagement and inhibition

How can researchers distinguish between direct and indirect mechanisms affecting NTRK1 phosphorylation at Tyr680/681?

Distinguishing between direct kinase inhibition and indirect regulation of NTRK1 phosphorylation requires sophisticated experimental design:

Mechanistic Dissection Strategy:

• Kinase Domain Mutant Analysis:

  • Generate NTRK1 kinase-dead mutants (K547R) to eliminate autophosphorylation

  • Compare phosphorylation patterns between wild-type and kinase-dead NTRK1

  • Any phosphorylation detected in kinase-dead mutants must be mediated by other kinases

• Temporal Signaling Cascade Analysis:

  • Design time-course experiments with selective inhibitors targeting:

    • Upstream kinases (e.g., Src family kinases)

    • NTRK1 itself (e.g., entrectinib)

    • Downstream effectors (e.g., MEK inhibitors)

  • Measure Tyr680/681 phosphorylation at multiple timepoints (5, 15, 30, 60, 120 min)

• Alternative Activation Pathway Investigation:

  • "We have identified a ligand-independent mechanism whereby the tumor suppressor, TP53, induces nerve growth factor receptor, NTRK1, phosphorylation at Y674/Y675 (NTRK1-pY674/pY675), via the repression of the NTRK1-phosphatase, PTPN6."

  • Experimental design to distinguish pathways:

    • NGF stimulation (direct activation)

    • TP53 activation with nutlin-3a (indirect activation)

    • Compare phosphorylation patterns and kinetics between pathways

• Phosphatase Regulation Assessment:

  • Identify phosphatases that target Tyr680/681 (e.g., PTPN6)

  • Use phosphatase inhibitors to evaluate contribution to phosphorylation status

  • Measure phosphatase activity in parallel with phosphorylation levels

• In Vitro Kinase Assays:

  • Purify recombinant NTRK1 kinase domain

  • Test direct phosphorylation by candidate kinases

  • Confirm sites of phosphorylation by mass spectrometry

• Cellular Microenvironment Factors:

  • "NTRK1 overexpression correlated with a significant reduction of the total T cell infiltrate within the primary tumor, likely due to the significant reduction in total CD8+ T cells."

  • Design co-culture experiments to evaluate immune cell contributions to NTRK1 phosphorylation

This comprehensive approach enables researchers to determine whether changes in NTRK1 phosphorylation are due to direct receptor activation, cross-talk from other signaling pathways, or alterations in regulatory phosphatase activity.

What advanced techniques can be combined with phospho-specific antibodies to study NTRK1 in complex tissue environments?

Integrating phospho-NTRK1 antibodies with cutting-edge technologies enables sophisticated analysis of receptor activation in complex tissues:

Advanced Multimodal Analysis Techniques:

• Spatial Transcriptomics with Phosphoprotein Detection:

  • Combine in situ RNA sequencing with phospho-NTRK1 immunofluorescence

  • Co-register gene expression patterns with protein phosphorylation status

  • Map microenvironmental factors influencing NTRK1 activation

• Multi-Epitope Ligand Cartography (MELC):

  • Sequential immunolabeling and imaging of up to 100 proteins on the same tissue section

  • Include phospho-NTRK1 (Tyr680/681) in antibody panel

  • Correlate NTRK1 phosphorylation with:

    • Cell type markers

    • Other phosphorylated RTKs

    • Downstream signaling molecules

    • Microenvironmental features

• Phospho-Mass Cytometry (Phospho-CyTOF):

  • Metal-tagged antibodies for high-dimensional single-cell analysis

  • Panel design: Include phospho-NTRK1 with lineage markers and other phospho-proteins

  • Data analysis: Apply unsupervised clustering to identify cell populations with distinct NTRK1 activation states

• Proximity Ligation Assay (PLA):

  • Detect protein-protein interactions involving phosphorylated NTRK1

  • Applications:

    • NTRK1 dimerization

    • Recruitment of adaptor proteins (SHC1, FRS2)

    • Association with negative regulators

• CLARITY with Phospho-Immunostaining:

  • Clear, Lipid-exchanged, Anatomically Rigid, Imaging/immunostaining compatible, Tissue hYdrogel

  • 3D visualization of phospho-NTRK1 distribution in intact neural tissues

  • Trace activated NTRK1-positive neural circuits throughout brain regions

• Patient-Derived Organoids with Live Phosphorylation Imaging:

  • Generate 3D organoids from patient tissues

  • Transduce with FRET-based NTRK1 phosphorylation sensors

  • Real-time monitoring of phosphorylation dynamics during drug treatment

• Case Study Application in Neural Tissues:

  • "Using this antibody, we performed immunohistochemical staining of the brain tissues of adult mice to examine NTRK1 localization. Distinct signals were observed in regions with known NTRK1 expression, such as the striatum and basal forebrain. The characteristic expression pattern of NTRK1 in the paraventricular thalamic nucleus (PVT) was verified at the protein level, with high and low expression levels in the anterior and posterior PVT, respectively."